Three years after its initial investment and two years after inking a research collaboration to discover drugs for schizophrenia, Takeda Pharmaceutical Co. Ltd. found Envoy Therapeutics Inc. irresistible, snagging the privately held company for up to $140 million in cash, including an undisclosed up-front payment and progress-dependent, preclinical milestone payments.
Shares of MEI Pharma Inc. (NASDAQ:MEIP) popped on Monday morning and climbed throughout the day after the company disclosed a $27.5 million private placement.
The Supreme Court is expected to hear oral arguments in Amgen Inc. v. Connecticut Retirement Plans and Trust Funds, in which the big biotech is appealing a decision from the Court of Appeals for the Ninth Circuit that upheld a federal district court's refusal to hear evidence rebutting fraud-on-the-market claims involving erythropoietins before it certified a class in the shareholder lawsuit.
With government offices still hampered by the cleanup from Hurricane Sandy, the FDA was several days late responding to Cornerstone Therapeutics Inc.'s new drug application for lixivaptan. The decision, reported Thursday, was no shocker.
Although privately held Drais Pharmaceuticals Inc. began operations five years ago, the Bridgewater, N.J.-based company reinvented itself in 2012 to shelter development projects as virtual biotechs.
Sanofi SA, which reported third-quarter results last week, placed its pipeline challenges front and center, noting "business [earnings per share] reflects patent expirations."
On a day when all eyes in the U.S. were trained on the path of destruction left by Hurricane Sandy, the CHDI Foundation Inc. was focused on a very different destroyer: Huntington's disease (HD).
In a two-day meeting that begins this morning, the FDA's Drug Safety and Risk Management (DSaRM) Advisory Committee (adcom) will examine the potential impact of rescheduling hydrocodone combination products – those mixed with other analgesics or as an antitussive – from Schedule III to II, similar to hydrocodone alone.
Nearly one in four marketed drugs contains the chemical element fluorine, including household names for vastly different indications such as Lipitor (atorvastatin, Pfizer Inc.), Cipro (ciprofloxacin, Bayer AG) and Prozac (fluoxetine, Eli Lilly and Co.)
Sanofi SA, which reported third-quarter results Thursday, placed its pipeline challenges front and center, noting "business [earnings per share] reflects patent expirations."
